This Cheap Biotech Offers Investors a Play on ALS If Trial Data Continues to Impress
This Cheap Biotech Offers Investors a Play on ALS If Trial Data Continues to Impress
如果临床试验数据继续令人印象深刻，这家廉价的生物科技公司将为投资者提供一个关于肌萎缩性侧索硬化症的投资机会。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册